PR out this morning I C :)I like this a lot!!!!! Put out by SEC FILINGS. I'm not familiar with them. Great exposure though and I like this portion of the article:
The Upshot
Cardiol Therapeutics is pursuing the development of its CBD formulations to initially address an orphan disease, the accelerated regulatory approval path that has proven successful for GW Pharma. For GW Pharma, success in developing its CBD formulation, Epidiolex, through to FDA approval resulted in the creation of over $5 billion in shareholder value between 2014 and 2018. The fact that Cardiol is developing its CBD formulation for an orphan disease indication (acute myocarditis) with an addressable market almost twice the size of GW Pharma's, serves to illustrate the value creation potential of Cardiol Therapeutics.
Acute myocarditis affects roughly twice as many patients as do the rare forms of epilepsy treated by Epidiolex, and, importantly, Cardiol has other lines in the water with the pending launch of its commercial CBD product and its research program into CBD as a treatment for heart failure. Chronic heart failure is a far more prevalent condition than myocarditis, affecting over six million people in North America, with associated healthcare costs exceeding $30 billion annually in the U.S. alone.
Cardiol is well funded, having recently closed a round of $17.25 million. The company also recently brought on board CNBC analyst and Wall Street veteran Steven Grasso to raise its profile in the U.S. investment community. Cardiol Therapeutics is charging forward, and investors should take note of this growing company.
Please follow the link to read the full article: https://www.secfilings.com/news/orphan-drug-designation-is-proven-path-for-cbd-147
About SECFilings.com
Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members.